Symptomatic severe aortic stenosis (AS) is the most common indication for valvular interventions.
Symptomatic severe aortic stenosis (AS) is the most common indication for valvular interventions. 1 AS is a degenerative and progressive disease that characteristically remains asymptomatic for decades but once symptoms occur, survival is severely compromised.
Historical data have shown that the time from the onset of symptoms to death is about 2 years in patients who develop heart failure (HF) symptoms, 3 years in those who present with a syncope and 5 years in those presenting with angina. 2 The Long-term follow-up of the Placement of Aortic Transcatheter Valves (PARTNER 1B) trial showed that two-thirds of inoperable patients who followed standard treatment did not survive beyond 2 years, while transcatheter aortic valve replacement (TAVR) halved mortality. 
Prevalence of Heart Failure and Related Comorbidities
HF is multifactorial in patients with severe AS and can be a consequence of the increased afterload and myocardial remodeling, with the contributory effect of cardiac damage characteristics of stages 2-4, or secondary to ischaemia. 4 Characterising the aetiology requires interrogation and assessment of previous MI or coronary artery disease, status of coronary artery lesions (i.e. existence of lesions requiring intervention), atrial fibrillation and pulmonary hypertension.
Defining prior congestive HF is not standardised and may range from ambulatory symptoms prior to hospitalisations for HF. In Table 1 we summarise the baseline characteristics of seven clinical trials, providing data for both the TAVR and control groups when available. [7] [8] [9] [10] [11] [12] [13] Prior MI ranged from 5% in a study with an all-comers design to 31% in an extreme risk cohort; 14 coronary artery disease affected two-thirds of patients and atrial fibrillation one-third. [7] [8] [9] [10] [11] [12] [13] Remarkably, previous HF was captured only in three of the seven studies, and was highly prevalent (≥95%) in patients with intermediate, high or extreme risk. [7] [8] [9] [10] [11] [12] LVEF was reported in four of seven studies and mean values were always above the cut-off value accepted for normality (>50%). An ejection fraction <50% was seen in ~30-50% of patients with severe AS. [7] [8] [9] 12 The New York Heart Association (NYHA) functional class at baseline was used in all studies and reflected accurately the risk of the analysed cohorts. In an all-comers design, 13 approximately half of the patients presented with NYHA class I or II (Table 1) , while this number was less than 10% in cohorts with high or extreme risk. 7, 8, 12 Likewise, NYHA class IV was present in up to half of patients at high surgical risk, while it was observed in <3% in the all-comers cohort. 12, 13 These findings underscore the value of NYHA class for characterising the baseline functional status of patients with severe AS. Although the reproducibility of this assessment has been criticised, its simplicity and availability make it a useful functional assessment. 15 It is noteworthy that prior congestive HF should be better defined and standardised and consistently captured in cardiovascular trials. In cardiovascular research, all-cause mortality is considered the most robust and unbiased clinical endpoint ( Figure 2) . 16 Nevertheless, it may lack specificity, and thus differentiation between cardiovascular and non-cardiovascular death is compulsory. Given the complexity in classifying events as cardiovascular or non-cardiovascular, the involvement of an independent clinical events committee is considered a quality marker when interpreting trial outcomes. 16 It has been suggested that using cardiovascular death in composite primary endpoints instead of all-cause mortality, for example cardiovascular death and hospitalisations for HF, reduces statistical noise generated by non-cardiovascular fatal events that are generally not influenced by targeted cardiovascular interventions. 17 
Hospitalisation due to Heart Failure
Although rehospitalisation due to HF is considered a less robust endpoint in clinical trials due to the lack of implementation of standardised definitions, it remains the most important outcome from patient prognosis and health economic perspectives. In three of the seven trials included in this review it was not reported, and definitions slightly varied when it was available. 7, 10, 13 Frequently, it is difficult to distinguish between a hospitalisation due to aortic valve disease and/or complications of the valve procedure versus a hospitalisation due to HF. These are not always mutually exclusive and strict criteria should be applied to be able to adjudicate and report both. A standardised definition of hospitalisation due to HF is needed if meaningful comparison of rates among cardiovascular trials are to be made. 16 The 
Health Status Measures
The impact of transcatheter therapies for severe AS on functional capacity has been largely assessed by changes in NYHA class and, less frequently, by the use of validated disease-specific questionnaires such as the Kansas City Cardiomyopathy Questionnaire (KCCQ).
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When interpreting comparisons of cross-sectional measures, it is important to take into account that generally subjects will be not all be present for any specific follow-up time point, due to death, a missed appointment or patients lost to follow-up. Consequently, these comparisons will unequivocally exclude patients who are the most ill. Aortic valve replacement has significantly and consistently increased the number of patients classified as NYHA class I, ranging from a 24% increase relative to baseline in inoperable patients, to
an 80% increase in all-comer populations at one-year follow-up. 8, 13 Likewise, the frequency of NYHA class III and IV has been reduced up to 65% and 50% respectively in high-risk cohorts ( Table 2 ).
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The KCCQ is a 23-item, self-administered instrument that quantifies (TAVR UNLOAD) trial. 27 The high frequency of recurrent HF events is denoted in trials such as the PARADIGM HF, in which one-third of patients who were hospitalised once during follow-up were hospitalised at least for a second time throughout the duration of the trial, and one tenth were hospitalised three or more times. 28 Similar distribution of recurrent events have been reported in drug and device intervention trials. [29] [30] [31] [32] [33] Patients with more unplanned 
hospitalisations exhibit a worse quality of life and survival, thus, being able to analyse recurrent hospitalisations not only better characterises the disease but also increases statistical power to detect differences in treatment effects.
Since the early 1980s, several statistical approaches to account for multiple hospitalisations have been introduced (Table 3) , and recently a shift towards these more complex methods has been observed in trials enrolling patients with HF, aiming for efficiency and robustness. 28, [34] [35] [36] 28, 38 The choice for the most appropriate statistical approach relates to:
• The distribution of timing of subsequent events -HF rehospitalisations may not occur after similar intervals but in clusters where some patients will present multiple adjacent episodes and others no recurrences.
• The within-patient correlation of subsequent events -it is known that hospitalisations beget more hospitalisations and worse prognosis, thus methods assuming independence of recurrent events may not be preferred for analysis of HF events.
• Frequency of the recurrent and terminal events -where methods that analyse death as non-informative censoring or as a recurrent event may not be ideal for cohorts in which mortality is expected to be relatively high.
A conservative approach is to include a method for a primary statistical analysis based on the study assumptions, and provide sensitivity analyses based on other methods for robustness. 
Alternative approaches include the use of methods based on event rates, such as the Poisson regression and negative binomial regression. The latter allows for more flexibility but assuming a constant event rate over time and not analysing death as a competing risk, thus it may not be preferred in scenarios where fatal events account for a high proportion of the composite. Of interest in this situation is the Gosh and Lin cumulative incidence method, which handles fatal events as informative censoring. 39 In a recent pre-specified sub-analysis of the PARADIGM-HF trial, the authors compared results of the analysis of recurrent hospitalisations using a cumulative incidence method, time-to-event models (WLW, LWYY and the joint frailty model) and the negative binomial model.
All approaches provided similar estimates for the effect of the experimental therapy (sacubitril/valsartan) when compared with the traditional time-to-first-event analysis (log-rank test). 28 The authors concluded that no single method can be recommended over another, and the preferred statistical approach for a specific trial should be discussed with regulatory agencies. 26 It is noteworthy that the joint frailty and the LWYY methods offer advantages that have prompted their use in recent studies (Table 3) . 17, 28, 40 Generalised pairwise comparison (GPC) methods have been developed, which use non-parametric approaches to compare outcomes on the basis of pairs of subjects. 41 Hierarchical GPC methods include the Finkelstein-Schoenfeld method, the unmatched Pocock method (or win ratio) and the Buyse method, among others. 35, 42, 43 These methods allow the creation of a hierarchy that gives a higher priority to the most severe outcomes and are able to accommodate multiple events. Characteristically, GPC methods are used for binary outcomes, such as in the primary endpoint of the Tafamidis (related to HF, symptomatic aortic valve disease or non-disabling stroke) and change in KCCQ relative to baseline. 27, 44 Non-hierarchical GPC methods include the O'Brien method. 45 Little is known about the relative benefits of one method over another. The FinkelsteinSchoenfeld method is currently the GPC method most widely used in cardiovascular research.
Conclusion
HF events, impaired functional status and reduced disease-specific quality of life are highly prevalent in patients with aortic stenosis and are significantly and positively affected by aortic valve interventions.
The use of standardised definitions for HF-related events is recommended to improve our understanding of the disease and to allow comparisons among clinical trials. Further research on complex statistical approaches, which take into account the occurrence of multiple events, is warranted.
